MeiraGTx (MGTX) Sets New 12-Month High at $24.28

MeiraGTx Holdings PLC (NASDAQ:MGTX) shares reached a new 52-week high on Tuesday . The stock traded as high as $24.28 and last traded at $23.69, with a volume of 44656 shares traded. The stock had previously closed at $23.43.

MGTX has been the topic of several research analyst reports. Chardan Capital reissued a “buy” rating and issued a $30.00 price objective on shares of MeiraGTx in a research report on Thursday, January 31st. Zacks Investment Research raised MeiraGTx from a “hold” rating to a “buy” rating and set a $20.00 price target on the stock in a research report on Saturday, March 30th. Finally, Barclays upped their price target on MeiraGTx from $20.00 to $30.00 and gave the company a “positive” rating in a research report on Wednesday, May 15th. Five analysts have rated the stock with a buy rating, The stock presently has an average rating of “Buy” and a consensus price target of $27.75.

The company has a market capitalization of $782.82 million and a price-to-earnings ratio of -5.40. The company has a quick ratio of 4.82, a current ratio of 6.96 and a debt-to-equity ratio of 0.02.

MeiraGTx (NASDAQ:MGTX) last announced its quarterly earnings data on Tuesday, May 14th. The company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($0.64) by $0.02. The firm had revenue of $0.79 million for the quarter. Equities analysts forecast that MeiraGTx Holdings PLC will post -3.12 EPS for the current year.

In other news, major shareholder Life Sciences Maste Perceptive acquired 1,304,348 shares of MeiraGTx stock in a transaction dated Friday, March 1st. The shares were purchased at an average cost of $13.80 per share, for a total transaction of $18,000,002.40. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink.

Several institutional investors have recently made changes to their positions in MGTX. BlackRock Inc. acquired a new stake in shares of MeiraGTx in the 3rd quarter worth about $1,968,000. IFP Advisors Inc increased its holdings in MeiraGTx by 3,697.6% in the fourth quarter. IFP Advisors Inc now owns 75,192 shares of the company’s stock worth $725,000 after purchasing an additional 73,212 shares in the last quarter. SG Americas Securities LLC bought a new stake in MeiraGTx in the fourth quarter worth approximately $138,000. Northern Trust Corp increased its holdings in MeiraGTx by 51.7% in the fourth quarter. Northern Trust Corp now owns 40,913 shares of the company’s stock worth $395,000 after purchasing an additional 13,936 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of MeiraGTx by 54.1% during the fourth quarter. Geode Capital Management LLC now owns 16,625 shares of the company’s stock valued at $160,000 after acquiring an additional 5,834 shares in the last quarter. Hedge funds and other institutional investors own 21.81% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was originally posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this article on another domain, it was stolen and republished in violation of United States and international copyright and trademark law. The original version of this article can be read at

About MeiraGTx (NASDAQ:MGTX)

MeiraGTx Holdings plc, a clinical-stage gene therapy company, focusing on developing treatments for patients living with serious diseases. The company develops various therapies for ocular diseases, including rare inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; neurodegenerative diseases, such as amyothrophic lateral sclerosis; and Parkinson's diseases.

Featured Article: Should you buy a closed-end mutual fund?

Receive News & Ratings for MeiraGTx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MeiraGTx and related companies with's FREE daily email newsletter.